Market Overview

Benzinga's Top Downgrades

Share:
Related BMRN
Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey
Your Guide To 2017's Emerging Pharmaceuticals Catalysts
Marketplace Roundtable: Biotech Hanging In The Balance (Seeking Alpha)
Related PEG
Benzinga's Top Upgrades, Downgrades For February 27, 2017
10 Stocks To Watch For February 24, 2017

Analysts at Deutsche Bank downgraded BioMarin Pharmaceutical (NASDAQ: BMRN) from “buy” to “hold.” BioMarin's shares closed at $38.70 on Friday. BioMarin's trailing-twelve-month ROE is -11.59%.

Analysts at FBR Capital downgraded Public Service Enterprise Group (NYSE: PEG) from “market perform” to “underperform.” PSEG's stock closed at $32.13 on Friday. PSEG's PEG ratio is 6.66.

Analysts at KeyBanc Capital downgraded Ignite Restaurant Group (NASDAQ: IRG) from “buy” to “hold.” Ignite Restaurant's shares closed at $15.12 on Friday. Ignite Restaurant's trailing-twelve-month profit margin is 2.99%.

UBS downgraded Westlake Chemical (NYSE: WLK) from “neutral” to “sell.” Westlake Chemical's shares closed at $69.50 on Friday. Westlake Chemical's trailing-twelve-month ROA is 9.24%.

Latest Ratings for BMRN

DateFirmActionFromTo
Mar 2017NomuraInitiates Coverage OnNeutral
Feb 2017Morgan StanleyInitiates Coverage OnOverweight
Jan 2017Credit SuisseAssumesOutperformOutperform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (BMRN + IRG)

View Comments and Join the Discussion!